FDA approves once-monthly injection for opioid use disorder: 4 things to know

The FDA approved Sublocade, Indivior's once-monthly buprenophine injection, to treat opioid use disorder in adults with moderate-to-severe addiction.

Here are four things to know.

1. Buprenophine for opioid use disorder was previously approved to administer in a tablet, dissolving film and implant form. Sublocade provides a new option for patients who may want to reduce the burden of taking a daily tablet. 

2. Sublocade is the first monthly injectable buprenophine treatment.

3. The approval comes after an FDA advisory committee voted 18-1 that the injectable drug could benefit addicts.

4. The injection is expected to be available to US patients in the first quarter of 2018. 

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars